EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Guiding model‐driven combination dose selection using multi‐objective synergy optimization

Jana L Gevertz iD, Irina Kareva

CPT: Pharmacometrics & Systems Pharmacology · 2023-11 · 12 (11) · 1698-1713

DOI: 10.1002/psp4.12997 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 06.07.2023. Verfasst von Jana L Gevertz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics and Statistics, The College of New Jersey, Ewing, New Jersey, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Algorithms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi‐Objective Optimization of Combination Synergy – Dose Selection (MOOCS‐DS) method for using drug synergy as a tool for guiding dose selection for a combination of preselected compounds. This method decouples synergy of potency (SoP) and synergy of efficacy (SoE) and identifies Pareto optimal solutions in a multi‐objective synergy space. Using a toy combination therapy model, we explore properties of the MOOCS‐DS algorithm, including how optimal dose selection can be influenced by the metric used to define SoP and SoE. We also demonstrate the potential of our approach to guide dose and schedule selection using a model fit to preclinical data of the combination of the PD‐1 checkpoint inhibitor pembrolizumab and the anti‐angiogenic drug bevacizumab on two lung cancer cell lines. The identification of optimally synergistic combination doses has the potential to inform preclinical experimental design and improve the success rates of combination therapies. Jel classificationDose Finding in Oncology

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsAlgorithmsHumansDrug SynergismCombined Modality TherapyCell Line, Tumor

Autor:innen und Institutionen

  • Department of Mathematics and Statistics, The College of New Jersey, Ewing, New Jersey, USA.
  • Quantitative Pharmacology Department, EMD Serono, Merck KGaA, Billerica, Massachusetts, USA.

ORCID-Profile: Jana L Gevertz

Zitieren

APA

Gevertz, J. L., & Kareva, I. (2023). Guiding model‐driven combination dose selection using multi‐objective synergy optimization. CPT: Pharmacometrics & Systems Pharmacology, 12(11), 1698-1713. https://doi.org/10.1002/psp4.12997

Vancouver

Gevertz JL, Kareva I. Guiding model‐driven combination dose selection using multi‐objective synergy optimization. CPT: Pharmacometrics & Systems Pharmacology. 2023;12(11):1698-1713. doi:10.1002/psp4.12997

BibTeX
@article{Gevertz2023,
  author = {Gevertz, Jana L and Kareva, Irina},
  title = {Guiding model‐driven combination dose selection using multi‐objective synergy optimization},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2023},
  volume = {12},
  number = {11},
  pages = {1698--1713},
  doi = {10.1002/psp4.12997}
}
Kostenlos starten →